Full Press Release Details
Projects 211% Increase in CGuard EPS
Sales for the Fourth Quarter of 2017
call to be held at 10AM Eastern today to discuss recent developments, preliminary sales results and proposals for upcoming shareholder
Aviv, Israel- January 10, 2018 - InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus
management technologies and neurovascular devices, today announced preliminary unaudited sales results for the fourth quarter
of 2017. The Company anticipates sales of approximately $833,000 for the fourth quarter of 2017, compared to $322,000 for the
same period last year. This represents an approximately 159% increase, which is primarily due to increased sales of CGuard EPS.
The Company anticipates a 211% increase in sales of CGuard EPS to approximately $606,000, compared to $195,000 for the
same period last year.
Barry, PhD, Chief Executive Officer of InspireMD, commented, "CGuard EPS is not only gaining acceptance among key
opinion leaders (KOLs) that treat carotid artery disease, but these physicians are now asking us, unsolicited, to be more involved
with our program. We believe this growing interest, combined with our specialized distribution network, positions us for even
stronger sales growth as these KOLs support our expansion into the mainstream group of users that include vascular surgeons, interventional
cardiologists, interventional radiologists and interventional neuroradiologists. In addition to Europe, we are now establishing
a foothold in Asia, evidenced by recent distribution agreements in India, Hong Kong, Taiwan, Australia, New Zealand and Vietnam.
For these and other reasons, we are extremely encouraged heading into 2018."
Company plans to host a conference call today, Wednesday, January 10th, at 10:00 a.m. Eastern Time to discuss recent
developments, preliminary unaudited fourth quarter 2017 sales results, and proposals under consideration for the upcoming shareholder
meeting. A link to the Company's definitive proxy statement is available at: https://www.sec.gov/Archives/edgar/data/1433607/000149315217015034/def14a.htm.
conference call will be available via telephone by dialing toll free 877-407-0782 for U.S. callers or +1 201-689-8567 for international
callers, or on the Company's Investor Relations section of the website: http://www.inspiremd.com/en/investors/investor-relations/.
webcast will also be archived on the Company's website and a telephone replay of the call will be available approximately
one hour following the call, through midnight January 24, 2018, and can be accessed by dialing 877-481-4010 for U.S. callers or
+1 919-882-2331 for international callers and entering conference ID: 23561.
seeks to utilize its proprietary MicroNet technology to make its products the industry standard for embolic protection
and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization,
no reflow and major adverse cardiac events.
intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard ), neurovascular, and peripheral
artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants
are quoted on the NYSE American under the ticker symbol NSPR.WS.
press release contains "forward-looking statements." Such statements may be preceded by the words "intends,"
"may," "will," "plans," "expects," "anticipates," "projects,"
"predicts," "estimates," "aims," "believes," "hopes," "potential"
or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot
be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking
statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance
of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability
to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much
larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities
and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third
party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering
our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and
foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need
to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive
or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign
currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws
and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors
that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities
and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.